Pharmaceutical intelligence for Bicara Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

ClinicalAugust 14, 2026

Phase I/II Trial of Ficerafusp Alfa with Pembrolizumab and SBRT in HPV-Negative HNSCC

An open-label phase I/II trial is underway to evaluate ficerafusp alfa, pembrolizumab, and SBRT in patients with high-risk, locoregionally advanced HPV-negative HNSCC.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalAugust 14, 2026

Phase I/II Trial of Ficerafusp Alfa with Pembrolizumab and SBRT in HPV-Negative HNSCC

An open-label phase I/II trial is underway to evaluate ficerafusp alfa, pembrolizumab, and SBRT in patients with high-risk, locoregionally advanced HPV-negative HNSCC.

Competitive activity

No signals indexed for this entity yet.

Assets

Pembrolizumab →

Therapeutic areas

Head and Neck Cancer →

Oncology →

Indications

Head and Neck Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.